Difference between revisions of "Abiraterone"
Jump to navigation
Jump to search
| (2 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
==See also== | ==See also== | ||
*[[Enzalutamide]]. | |||
*[[Prostate cancer]]. | *[[Prostate cancer]]. | ||
*[[Androgen receptor]]. | |||
==References== | ==References== | ||
| Line 9: | Line 11: | ||
[[Category:Genitourinary pathology]] | [[Category:Genitourinary pathology]] | ||
[[Category:Clinical]] | [[Category:Clinical]] | ||
[[Category:Drugs]] | |||
Latest revision as of 13:10, 18 March 2019
Abiraterone is an androgen synthesis inhibitor used to treat prostate cancer.[1]
See also
References
- ↑ Mitsiades, N. (Aug 2013). "A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.". Cancer Res 73 (15): 4599-605. doi:10.1158/0008-5472.CAN-12-4414. PMID 23887973.